Sam Brusco, Associate Editor02.15.24
Merit Medical Systems has secured U.S. Food and Drug Administration (FDA) 510(k) clearance for its Scout MD surgical guidance system.
Scout MD fortifies Merit’s oncology portfolio with technology to enhance diagnosing and treating breast and other soft tissue cancers. Included in the system are a radar localization system, mini reflector, delivery system, and brachy system.
The solution supports implanting up to four different reflector configurations. The reflectors were designed to pinpoint tumor location when implanted in abnormal breast or other tissue, in order to guide more precise excision.
Met hopes the targeted approach with Scout MD can minimize healthy tissue damage, lower chance of re-excision, and avoid the emotional and physical distress of a second surgery.
John Vincent Kiluk, MD, FACS, Breast Surgical Oncologist at the Moffitt Cancer Center and Professor of Oncologic Sciences at USF, said the company’s development of different reflectors with different signals will help surgeons better delineate the edges of tumor resection.
“The subsequent result of this surgical precision should improve a surgeon’s ability to obtain adequate margins on larger tumors and decrease the need for repeat surgery,” he told the press.
“This momentum has enabled us to collect valuable real-world evidence through physician feedback, giving us a better understanding of what’s needed to improve oncology care,” added Fred P. Lampropoulos, Merit’s chairman and CEO. “In turn, we’re developing new technologies, like SCOUT MD, that enhance the patient experience and reduce the burden breast cancer places on women worldwide. We’re honored to be a part of their care journey, and we intend to continue innovating for them.”
In October 2023, Merit Medical completed enrollment in its WRAPSODY Arteriovenous Access Efficacy (WAVE) pivotal trial.
Scout MD fortifies Merit’s oncology portfolio with technology to enhance diagnosing and treating breast and other soft tissue cancers. Included in the system are a radar localization system, mini reflector, delivery system, and brachy system.
The solution supports implanting up to four different reflector configurations. The reflectors were designed to pinpoint tumor location when implanted in abnormal breast or other tissue, in order to guide more precise excision.
Met hopes the targeted approach with Scout MD can minimize healthy tissue damage, lower chance of re-excision, and avoid the emotional and physical distress of a second surgery.
John Vincent Kiluk, MD, FACS, Breast Surgical Oncologist at the Moffitt Cancer Center and Professor of Oncologic Sciences at USF, said the company’s development of different reflectors with different signals will help surgeons better delineate the edges of tumor resection.
“The subsequent result of this surgical precision should improve a surgeon’s ability to obtain adequate margins on larger tumors and decrease the need for repeat surgery,” he told the press.
“This momentum has enabled us to collect valuable real-world evidence through physician feedback, giving us a better understanding of what’s needed to improve oncology care,” added Fred P. Lampropoulos, Merit’s chairman and CEO. “In turn, we’re developing new technologies, like SCOUT MD, that enhance the patient experience and reduce the burden breast cancer places on women worldwide. We’re honored to be a part of their care journey, and we intend to continue innovating for them.”
In October 2023, Merit Medical completed enrollment in its WRAPSODY Arteriovenous Access Efficacy (WAVE) pivotal trial.